Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback